Rigor Reviewed

Rigor-Reviewed Manuscript

Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.

Name: Αlpha¹ Rigor Record — Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.
Item: Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.
Rating: 100
Author: Αlpha¹

Bhatnagar P, Ahmad NN, Li X, Coghlan M, Kaplan LM, Farooqi IS

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 3 high issues for “Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Observational Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted secondary genetic analysis of a randomized controlled trial, with a clear scientific premise, adequate reporting of biological variables, ethics, key resources, statistics, data availability, and transparency. Minor reporting gaps include lack of explicit randomization/blinding details, power analysis, exact p-values, and reporting guideline reference, but these do not undermine the overall robustness.

Both reviewers classified the study as observational (secondary analysis of an RCT). The evaluation covered all eight dimensions; non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification checked only 2 tests (limited coverage), and the citation check found no retracted or unresolved references.

4 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites twin, family, and adoption studies, the role of MC4R in obesity, the prevalence of pathogenic MC4R mutations, and prior evidence that GLP-1 receptor agonists may be effective in MC4R deficiency. It also acknowledges limitations of prior treatments (e.g., dietary interventions less effective, MC4R agonist trials not demonstrating efficacy). The rationale for studying tirzepatide is clearly stated, and the hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on MC4R deficiency, its prevalence, and the challenges in treating it, and logically links this to the hypothesis that tirzepatide may be effective in this subgroup.

Evidence

paraphrase[Introduction, paragraph 2]

“Two studies have shown that intense dietary and physical activity interventions are less effective in children with MC4R deficiency, and weight reduction is harder to maintain in this group.”

paraphrase[Introduction, paragraph 3]

“Here, to investigate the efficacy of tirzepatide in people with MC4R deficiency, we examined genetic data obtained from participants in a randomized controlled trial (SURMOUNT-1) of people with a BMI ≥30 kg m−2, or ≥27 kg m−2 with at least one weight-related comorbidity, treated with tirzepatide versus placebo.”

paraphrase[Introduction, paragraph 2]

“While melanocortin receptor agonists can act as pharmacological chaperones to rescue signaling by some MC4R-mutant receptors in cells, clinical trials of a MC4R agonist have not demonstrated efficacy in this patient group.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise, citing prior work on MC4R deficiency and GLP-1 receptor agonists, and provides a logical rationale for the study.

Evidence

direct quote[Introduction, paragraph 2]

“GLP-1 receptor agonists predominantly target non-MC4R-dependent neural pathways in mice , and there is evidence from a small clinical study with liraglutide that they may be effective in people with MC4R deficiency.”